

3-1-06

I FW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Dominguez et al.

Serial No.: 10/826,982 Group Art Unit No.: 1624

Filed: April 15, 2004 Examiner: Kahsay Habte

For: SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

Docket No.: A-837

RESPONSE TO RESTRICTION REQUIREMENT AND ELECTION OF SPECIES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Examiner Habte:

This is in response to an Office Action mailed on January 27, 2006, imposing an election of species/restriction requirement in the above-captioned patent application. The shortened one-month statutory period for response to the Office Action expires on February 27, 2006.

Accordingly, Applicants believe that this response is timely filed.

Applicants believe no fees are due at this time. However, should any fees be due, the Patent Office is hereby authorized to charge any additional fees required for this filing, or credit any overpayment, to Deposit Account No. 01-0519.

In response to the election/restriction requirement, Applicants provisionally elect, for search purposes and without prejudice, the species of {4-[5-methyl-6-piperidin-4-yl-3-(3-trifluoromethyl-phenyl)-pyridazin-4-yl]-pyrimidin-2-yl}-(1-phenyl-ethyl)-amine, to begin examination. This compound is specifically disclosed in the application as Example 12 on page 27. Claim 1 reads on the elected species.

EXPRESS MAIL CERTIFICATE

"Express Mail" mail labeling number:	EV732696493US	Date of Deposit:	February 27, 2006
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.			
<u>Dee Dee Sutherland</u> <small>Printed Name</small>		<u>Dee Dee Sutherland</u> <small>Signature</small>	

Respectfully submitted,

G. Prabhakar Reddy

G. Prabhakar Reddy
Attorney for Applicant
Registration No.: 47,890
Phone: (805) 447-3288
Date: February 27, 2006

Please send all future correspondence to:

US Patent Operations/GPR
Dept. 4300, M/S 28-2-C
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799